# PEMMELA (NCT04287829)

> Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients

No report yet. It can be ordered.

- Drugs tested: pembrolizumab plus lenvatinib
- Indication: second-line and third-line malignant pleural mesothelioma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04287829
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Mesotheliomas Pleural
- Interventions: Pembrolizumab; Lenvatinib
- Enrollment: 58
- Primary outcome: Objective response rate defined by Modified RECIST 1.1 criteria for pleural mesothelioma

## Indexed commentary on PEMMELA so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X
- 3 YouTube videos

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pemmela-nct04287829

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04287829", "email": "<work email>"}; the inbox owner confirms by the emailed link.